DiaSorin (OTCMKTS:DSRLF) Downgraded to Neutral Rating by UBS Group

Key Points

• UBS downgraded DiaSorin (DSRLF) from a "buy" to a "neutral" rating in a note to investors.
• Analyst coverage is mixed—two analysts rate the stock Buy and three rate it Hold, leaving an average consensus rating of "Hold."
• DSRLF opened at $67.00, trading below its 50‑day SMA ($77.81) and 200‑day SMA ($80.14), with a 1‑year range of $66.50 to $112.30.

DiaSorin (OTCMKTS:DSRLF - Get Free Report) was downgraded by stock analysts at UBS Group from a "buy" rating to a "neutral" rating in a note issued to investors on Thursday.

Several other analysts have also commented on DSRLF. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of DiaSorin in a research report on Tuesday, February 10th. BNP Paribas Exane upgraded DiaSorin to a "neutral" rating in a research note on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold".

DiaSorin Price Performance

DSRLF stock opened at $67.00 on Thursday. The stock's fifty day simple moving average is $77.81 and its two-hundred day simple moving average is $80.14. DiaSorin has a 1-year low of $66.50 and a 1-year high of $112.30.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company's shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin's business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.